PureTech Health plc Stock
Stocks
PRTC
GB00BY2Z0H74
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Cboe Europe
10:56:28 10/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 121.30 GBX | +0.41% |
|
-3.73% | -2.96% |
| 09-09 | EARNINGS AND TRADING: Pebble Beach revenue grows as forecast | AN |
| 07-13 | PureTech Health announces first patient dosing in Celea phase 3 trial | AN |
| Market Cap | 398M 343M 323M 294M 550M 37.9B 552M 3.82B 1.48B 19.31B 1.5B 1.46B 61.17B | P/E 2026 * |
-3.58x | P/E 2027 * | -4.28x |
|---|---|---|---|---|---|
| Enterprise Value | 155M 134M 126M 115M 215M 14.79B 216M 1.49B 577M 7.54B 584M 571M 23.87B | EV / Sales 2026 * |
18x | EV / Sales 2027 * | 12.6x |
| Free-Float |
84.36% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| PRTC | Delayed | |
Xetra
| 0VQ | End-of-day quote | |
|
OTC Markets
| PTCHF | Delayed | |
|
CBOE
| PRTC | Real-time | |
|
Deutsche Boerse AG
| 0VQ | Delayed | |
|
Börse Stuttgart
| 0VQ | Delayed |
Last Transcript : PureTech Health plc
| 1 day | +0.33% | ||
| 1 week | -3.73% | ||
| Current month | -3.73% | ||
| 1 month | +2.10% | ||
| 3 months | -2.96% | ||
| 6 months | -3.12% | ||
| Current year | -2.96% |
| 1 week | 118 |  | 126 |
| 1 month | 113 | | 129.2 |
| Current year | 107.4 | | 143.6 |
| 1 year | 104.71 | | 143.6 |
| 3 years | 100.4 | | 238.5 |
| 5 years | 100.4 | | 410.66 |
| 10 years | 100.4 | | 447.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Lyne
CEO | Chief Executive Officer | 43 | 15/07/2025 |
Eric Elenko
PSD | President | 53 | 09/04/2024 |
Charles Sherwood
COO | Chief Operating Officer | - | 01/08/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Langer
BRD | Director/Board Member | 76 | 08/05/2015 |
John LaMattina
BRD | Director/Board Member | 76 | 01/01/2009 |
| Director/Board Member | 73 | 01/10/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/13/26 A | Buy | Founder | 112,509 | 0.0466% | ||
| 9/24/25 A | Buy | Chief Executive Officer | 81,051 | 0.0337% | ||
| 9/24/25 A | Buy | Director | 29,239 | 0.0122% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.41% | -3.73% | +5.11% | -40.25% | 398M | |
| +0.78% | -6.98% | -2.73% | +11.12% | 46.38B | |
| +0.17% | -0.74% | +407.28% | +546.58% | 44.51B | |
| -0.86% | -2.60% | +35.51% | +20.35% | 42.3B | |
| -0.14% | -2.98% | -0.04% | +82.21% | 39.91B | |
| 0.00% | -1.72% | +13.42% | +42.33% | 32.79B | |
| -3.44% | -2.43% | - | - | 17.13B | |
| -0.78% | -1.13% | +20.74% | +116.26% | 16.36B | |
| -0.11% | -3.76% | +12.33% | +30.49% | 14.31B | |
| -0.86% | -4.60% | +76.86% | +39.36% | 13.29B | |
| Average | -0.51% | -2.56% | +63.17% | +94.27% | 26.74B | |
| Weighted average by Cap. | -0.32% | -3.03% | +85.84% | +132.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.64M 7.43M 7M 6.38M 11.93M 822M 11.98M 82.94M 32.05M 419M 32.43M 31.73M 1.33B | 15.51M 13.35M 12.57M 11.45M 21.42M 1.48B 21.51M 149M 57.56M 752M 58.24M 56.97M 2.38B |
| Net income | -124M -107M -101M -91.62M -171M -11.81B -172M -1.19B -461M -6.02B -466M -456M -19.06B | -96.8M -83.3M -78.43M -71.46M -134M -9.21B -134M -930M -359M -4.69B -363M -356M -14.87B |
| Net Debt | -243M -209M -197M -179M -335M -23.11B -337M -2.33B -901M -11.77B -912M -892M -37.3B | -204M -175M -165M -150M -281M -19.38B -282M -1.96B -756M -9.87B -765M -748M -31.27B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/09/26 | GBX 121.30 | +0.41% | 19,740 |
| 09/09/26 | GBX 120.80 | -0.49% | 446,139 |
| 08/09/26 | GBX 121.40 | +0.66% | 538,425 |
| 07/09/26 | GBX 120.60 | -0.82% | 265,679 |
| 04/09/26 | GBX 121.60 | -3.49% | 837,632 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PRTC Stock
Select your edition
All financial news and data tailored to specific country editions
